Drug intelligence / Profile preview

MBX-MC-101

Development stage: Preclinical
Lead developer: Mybiotics Pharma
Modality: Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral, Vaginal

Overview

MBX-MC-101 is a live biotherapeutic product developed by MyBiotics Pharma. It is based on the company's MyCrobe technology, which enables the production and delivery of beneficial bacteria to restore and maintain healthy microbiota in the human body. Unlike traditional probiotics, this approach aims to overcome natural barriers to colonization and promote long-term microbiome restoration. MBX-MC-101 is being developed primarily for the treatment of antibiotic-associated diarrhea and vaginal flora imbalance (vaginal dysbiosis). The product is currently in preclinical development.

Beyond the preview

Go deeper on MBX-MC-101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MBX-MC-101.

Explore the full profile